Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
CMPX•Analyst coverage
The current average analyst rating on the shares is buy, with 14 strong buy or buy ratings, 1 hold rating and no sell or strong sell ratings.
Wall Street's median 12-month price target for Compass Therapeutics Inc. is $6.50, about 243.9% above its August 5 closing price of $1.89.
Reported Q2 results
| Metric | Actual |
|---|---|
| Q2 net loss | $25.15 million |
| Q2 loss per basic share | $0.13 |
Cash position and runway
Compass ended the second quarter with $180 million in cash and marketable securities and expects its runway into 2028.
Q2 loss widens on higher spending
Compass Therapeutics said its second-quarter net loss widened year over year on higher research and development and general and administrative expenses.
